{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:05:39Z","timestamp":1791115539883,"version":"4.1.0"},"reference-count":92,"publisher":"Portland Press Ltd.","issue":"2","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:p>Bone modelling and remodelling are cell-mediated processes responsible for the construction and reconstruction of the skeleton throughout life. These processes are chiefly mediated by locally generated cytokines and growth factors that regulate the differentiation, activation, work and life span of osteoblasts and osteoclasts, the cells that co-ordinate the volumes of bone resorbed and formed. In this way, the material composition and structural design of bone is regulated in accordance with its loading requirements. Abnormalities in this regulatory system compromise the material and structural determinants of bone strength producing bone fragility. Understanding the intercellular control processes that regulate bone modelling and remodelling is essential in planning therapeutic approaches to prevention and treatment of bone fragility. A great deal has been learnt in the last decade. Clinical trials carried out exclusively with drugs that inhibit bone resorption have identified the importance of reducing the rate of bone remodelling and so the progression of bone fragility to achieved fracture reductions of approx. 50%. These trials have also identified limitations that should be placed upon interpretation of bone mineral density changes in relation to treatment. New resorption inhibitors are being developed, based on mechanisms of action that are different from existing drugs. Some of these might offer resorption inhibition without reducing bone formation. More recent research has provided the first effective anabolic therapy for bone reconstruction. Daily injections of PTH (parathyroid hormone)-(1\u201334) have been shown in preclinical studies and in a large clinical trial to increase bone tissue mass and reduce the risk of fractures. The action of PTH differs from that of the resorption inhibitors, but whether it is more effective in fracture reduction is not known. Understanding the cellular and molecular mechanisms of PTH action, particularly its interactions with other pathways in determining bone formation, is likely to lead to new therapeutic developments. The recent discovery through mouse genetics that PTHrP (PTH-related protein) is a crucial bone-derived paracrine regulator of remodelling offers new and interesting therapeutic targets.<\/jats:p>","DOI":"10.1042\/cs20060046","type":"journal-article","created":{"date-parts":[[2006,12,13]],"date-time":"2006-12-13T09:12:33Z","timestamp":1166001153000},"page":"77-91","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["New mechanisms and targets in the treatment of bone fragility"],"prefix":"10.1042","volume":"112","author":[{"given":"T.\u00a0John","family":"Martin","sequence":"first","affiliation":[{"name":"St Vincent's Institute of Medical Research, University of Melbourne Department of Medicine, 9 Princes Street, Fitzroy, Victoria 3065, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ego","family":"Seeman","sequence":"additional","affiliation":[{"name":"Department of Medicine and Endocrinology, Austin Health, Heidelberg, Victoria 3081, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2006,12,11]]},"reference":[{"key":"2021120120385060900_B1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S8756-3282(01)00614-7","article-title":"Epidemiology of fractures in England and Wales","volume":"29","author":"van\u00a0Staa","year":"2001","journal-title":"Bone"},{"key":"2021120120385060900_B2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.berh.2005.06.010","article-title":"How to manage osteoporosis after the menopause","volume":"19","author":"Compston","year":"2005","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"2021120120385060900_B3","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","article-title":"Treatment of postmenopausal osteoporosis","volume":"359","author":"Delmas","year":"2002","journal-title":"Lancet"},{"key":"2021120120385060900_B4","first-page":"315","article-title":"Skeletal heterogeneity and the purposes of bone remodelling: implications for the understanding of osteoporosis","volume-title":"Osteoporosis","author":"Parfitt","year":"1996"},{"key":"2021120120385060900_B5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMp038101","article-title":"Periosteal bone formation: a neglected determinant of bone strength","volume":"349","author":"Seeman","year":"2003","journal-title":"N. Eng. J. Med."},{"key":"2021120120385060900_B6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF02013227","article-title":"Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age","volume":"10","author":"Lips","year":"1978","journal-title":"Calcif. Tissue Res."},{"key":"2021120120385060900_B7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0221-8747(82)90032-7","article-title":"Histomorphometric analysis of bone biopsies from the iliac crest of normal British subjects","volume":"4","author":"Vedi","year":"1982","journal-title":"Metab. Bone Dis. Relat. Res."},{"key":"2021120120385060900_B8","first-page":"115","article-title":"Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr. Rev."},{"key":"2021120120385060900_B9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF03187471","article-title":"Age-related changes in resorption cavity characteristics in human trabecular bone","volume":"1","author":"Croucher","year":"1991","journal-title":"Osteoporosis Int."},{"key":"2021120120385060900_B10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1359\/jbmr.2001.16.3.457","article-title":"Mechanical consequences of bone loss in cancellous bone","volume":"16","author":"Van\u00a0der\u00a0Linden","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr. Rev."},{"key":"2021120120385060900_B12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"2021120120385060900_B13","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","article-title":"Therapeutic approaches to bone diseases","volume":"289","author":"Rodan","year":"2000","journal-title":"Science"},{"key":"2021120120385060900_B14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S8756-3282(02)00975-4","article-title":"Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females","volume":"32","author":"Ciarelli","year":"2003","journal-title":"Bone"},{"key":"2021120120385060900_B15","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1359\/jbmr.2003.18.9.1657","article-title":"Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture","volume":"18","author":"Qui","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jbmr.5650050402","article-title":"Cancellous bone remodeling in type\u00a0I (postmenopausal) osteoporosis: Quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels","volume":"5","author":"Eriksen","year":"1990","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF01880415","article-title":"Trabecular and endocortical bone remodelling in postmenopausal osteoporosis: comparison with normal postmenopausal women","volume":"1","author":"Arlot","year":"1990","journal-title":"Osteoporosis Int."},{"key":"2021120120385060900_B18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(84)92506-6","article-title":"Serum bone gla-protein: a specific marker for bone formation in postmenopausal osteoporosis","volume":"i","author":"Brown","year":"1984","journal-title":"Lancet"},{"key":"2021120120385060900_B19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1056\/NEJM198903023200903","article-title":"Reduced bone mass in the daughters of women with osteoporosis","volume":"320","author":"Seeman","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"2021120120385060900_B20","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1359\/jbmr.2001.16.12.2267","article-title":"Sexual dimorphism in vertebral fragility is more the results of gender differences in bone gain than bone loss","volume":"16","author":"Duan","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S8756-3282(00)00301-X","article-title":"How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?","volume":"27","author":"Delmas","year":"2000","journal-title":"Bone"},{"key":"2021120120385060900_B22","first-page":"273","article-title":"Morphological basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis","volume":"4","author":"Parfitt","year":"1980","journal-title":"Miner. Electrolyte Metab."},{"key":"2021120120385060900_B23","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bone.2003.12.013","article-title":"Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography","volume":"34","author":"Borah","year":"2004","journal-title":"Bone"},{"key":"2021120120385060900_B24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S8756-3282(97)00170-1","article-title":"Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications","volume":"21","author":"Meunier","year":"1997","journal-title":"Bone"},{"key":"2021120120385060900_B25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"key":"2021120120385060900_B26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s002239900713","article-title":"Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis","volume":"65","author":"Gonnelli","year":"1999","journal-title":"Calcif. Tissue Int."},{"key":"2021120120385060900_B27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1359\/JBMR.0301231","article-title":"Relationship between pre-treatment bone resorption and vertebral fractures in postmenopausal osteoporotic women treated with risedronate","volume":"19","author":"Seibel","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B28","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1172\/JCI113725","article-title":"Bone turnover in postmenopausal osteoporosis","volume":"82","author":"Civitelli","year":"1988","journal-title":"J. Clin. Invest."},{"key":"2021120120385060900_B29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bone.2003.12.022","article-title":"Changes in bone mineral density explain little of the reduction in vertebral or non-vertebral fracture risk with anti-resorptive therapy","volume":"34","author":"Delmas","year":"2004","journal-title":"Bone"},{"key":"2021120120385060900_B30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jcem.87.3.8325","article-title":"Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis","volume":"87","author":"Johnell","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021120120385060900_B31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70\u00a0mg compared with once-weekly risedronate 35\u00a0mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated wtth risedronate","volume":"7","author":"Watts","year":"2004","journal-title":"J. Clin. Densitom."},{"key":"2021120120385060900_B34","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1359\/JBMR.050814","article-title":"Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD","volume":"20","author":"Watts","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079903125003125","article-title":"Efficacy of risedronate on clinical vertebral fractures within six months","volume":"20","author":"Roux","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"2021120120385060900_B36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2021120120385060900_B37","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","article-title":"Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis TROPOS study. Strontium ranelate reduces the risk of non vertebral fractures in post-menopausal women with osteoporosis: Treatment Of Peripheral Osteoporosis (TROPOS) Study","volume":"90","author":"Reginster","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021120120385060900_B38","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1359\/JBMR.050309","article-title":"The effects of strontium ranelate on bone remodeling and bone safety assessed by histomorphometry in patients with postmenopausal osteoporosis","volume":"20","author":"Arlot","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B39","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality: the material and structural basis of the gain and loss of bone strength","volume":"354","author":"Seeman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2021120120385060900_B40","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"key":"2021120120385060900_B42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s002230010036","article-title":"Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage","volume":"69","author":"Li","year":"2001","journal-title":"Calcif. Tissue Int."},{"key":"2021120120385060900_B43","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1359\/jbmr.2003.18.3.512","article-title":"Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra","volume":"18","author":"Komatsubara","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Brief report: Bisphosphonateinduced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2021120120385060900_B45","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021120120385060900_B46","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years'experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N. Eng. J. Med."},{"key":"2021120120385060900_B47","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single dose placebo-controlled study of ASMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B48","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1021\/jm049874c","article-title":"Non peptide \u03b1v\u03b23 antagonists. Part 11: discovery and preclinical evaluation of potent \u03b1v\u03b23 antagonists for the prevention and treatment of osteoporosis","volume":"47","author":"Coleman","year":"2004","journal-title":"J. Med. Chem."},{"key":"2021120120385060900_B49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1172\/JCI6145","article-title":"A selective inhibitor of the osteoclastic V-H+-ATPase prevents bone loss in both thyroparathyroidechomized and ovariectomized rats","volume":"106","author":"Visentin","year":"2000","journal-title":"J. Clin. Invest."},{"key":"2021120120385060900_B50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002230020046","article-title":"Human osteopetrosis and other sclerosing disorders: recent genetic developments","volume":"69","author":"de\u00a0Vernejoul","year":"2001","journal-title":"Calcif. Tissue Int."},{"key":"2021120120385060900_B51","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1359\/JBMR.040302","article-title":"The chloride channel inhibitor NS3736 prevents bone resorption in ovariectomized rats without changing bone formation","volume":"19","author":"Schaller","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B52","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S8756-3282(02)00675-0","article-title":"A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat","volume":"30","author":"Lark","year":"2002","journal-title":"Bone"},{"key":"2021120120385060900_B53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJM198507183130302","article-title":"Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification","volume":"313","author":"Sly","year":"1985","journal-title":"N. Eng. J. Med."},{"key":"2021120120385060900_B54","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone(1\u2013134) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2021120120385060900_B55","first-page":"690","article-title":"Anabolic actions of parathyroid hormone on bone","volume":"14","author":"Dempster","year":"1993","journal-title":"Endocr. Rev."},{"key":"2021120120385060900_B56","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S8756-3282(03)00202-3","article-title":"Anabolic and catabolic bone effects of human parathyroid hormone (1\u201334) are predicted by duration of hormone exposure","volume":"33","author":"Frolik","year":"2003","journal-title":"Bone"},{"key":"2021120120385060900_B57","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1210\/endo.136.8.7628403","article-title":"Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells","volume":"136","author":"Dobnig","year":"1995","journal-title":"Endocrinology"},{"key":"2021120120385060900_B58","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"J. Clin. Invest."},{"key":"2021120120385060900_B59","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1210\/endo.142.7.8306","article-title":"Minireview: transcriptional control of osteoblast differentiation","volume":"142","author":"Karsenty","year":"2001","journal-title":"Endocrinology"},{"key":"2021120120385060900_B60","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/me.2002-0225","article-title":"Parathyroid hormone bone anabolic action requires Cbfa1\/Runx2-dependent signalling","volume":"17","author":"Krishnan","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"2021120120385060900_B61","doi-asserted-by":"crossref","first-page":"50259","DOI":"10.1074\/jbc.M307444200","article-title":"Proteasomal degradation of Runx 2 shortens parathyroid hormone-induced apoptotic signalling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism","volume":"278","author":"Bellido","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2021120120385060900_B62","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes; a novel mechanism for hormonal control of ostioblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology"},{"key":"2021120120385060900_B63","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL receptor-related protein 5","volume":"346","author":"Boyden","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"2021120120385060900_B64","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"key":"2021120120385060900_B65","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrg1427","article-title":"Wnt and \u03b2-catenin signalling; diseases and therapies","volume":"5","author":"Moon","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"2021120120385060900_B66","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/jcb.20506","article-title":"Effects of parathyroid hormone on Wnt signalling pathway in bone","volume":"95","author":"Kulkarni","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"2021120120385060900_B67","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1517\/14728222.9.5.1063","article-title":"Wnt signalling pathway: a new target for the treatment of osteoporosis","volume":"9","author":"Rawadi","year":"2005","journal-title":"Expert Opin. Ther. Targets"},{"key":"2021120120385060900_B68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"237","author":"Keller","year":"2005","journal-title":"Bone"},{"key":"2021120120385060900_B69","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1\u201334) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.tem.2004.01.002","article-title":"Does bone resorption inhibition affect the anabolic response to parathyroid hormone?","volume":"15","author":"Martin","year":"2004","journal-title":"Trends Endocrinol. Metab."},{"key":"2021120120385060900_B71","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1043-2760(01)00460-X","article-title":"Reconstructing the skeleton with intermittent parathyroid hormone","volume":"12","author":"Seeman","year":"2001","journal-title":"Trends Endocrinol. Metab."},{"key":"2021120120385060900_B72","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B73","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2021120120385060900_B74","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2021120120385060900_B75","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2021120120385060900_B76","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molmed.2004.12.004","article-title":"Osteoclast-derived activity in the coupling of bone formation to resorption","volume":"11","author":"Martin","year":"2005","journal-title":"Trends Mol. Med."},{"key":"2021120120385060900_B77","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2021120120385060900_B78","first-page":"S23","article-title":"Parathyroid hormone-related protein: hormone and cytokine","volume":"154","author":"Martin","year":"1997","journal-title":"J. Endocrinol."},{"key":"2021120120385060900_B79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1152\/physrev.1996.76.1.127","article-title":"Defining the roles of PTHrP in normal physiology","volume":"76","author":"Philbrick","year":"1996","journal-title":"Physiol. Rev."},{"key":"2021120120385060900_B80","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1210\/endo-125-4-2022","article-title":"Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1\u201334 and PTH 1\u201334 on bone in rats","volume":"125","author":"Hock","year":"1989","journal-title":"Endocrinology"},{"key":"2021120120385060900_B81","first-page":"199","article-title":"Parathyroid hormone (PTH)-related protein (1\u201336) is equipotent to PTH(1\u201334) in humans","volume":"81","author":"Everhart-Caye","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021120120385060900_B82","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3565(24)29333-2","article-title":"Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone","volume":"299","author":"Nemeth","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021120120385060900_B83","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/dbio.1996.0104","article-title":"Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development","volume":"175","author":"Amizuka","year":"1996","journal-title":"Dev. Biol."},{"key":"2021120120385060900_B84","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S8756-3282(97)00180-4","article-title":"Temporal expression of PTHrP during endochondral bone formation in mouse and intramembranous bone formation in an in vivo rabbit model","volume":"21","author":"Kartsogiannis","year":"1997","journal-title":"Bone"},{"key":"2021120120385060900_B85","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/(SICI)1097-4652(199601)166:1<94::AID-JCP11>3.0.CO;2-P","article-title":"Expression of parathyroid hormone-related protein in cells of osteoblast lineage","volume":"166","author":"Suda","year":"1996","journal-title":"J. Cell. Physiol."},{"key":"2021120120385060900_B86","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1083\/jcb.126.6.1611","article-title":"Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation","volume":"126","author":"Amizuka","year":"1994","journal-title":"J. Cell Biol."},{"key":"2021120120385060900_B87","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1172\/JCI24918","article-title":"Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1\u201334","volume":"115","author":"Miao","year":"2005","journal-title":"J. Clin. Invest."},{"key":"2021120120385060900_B88","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"Laupacis","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"2021120120385060900_B89","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1359\/JBMR.050609","article-title":"Identification of osteopenic women at high risk of fracture: the OFELY Study","volume":"20","author":"Sornay-Rendu","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"2021120120385060900_B90","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S8756-3282(03)00200-X","article-title":"Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial","volume":"33","author":"Kanis","year":"2003","journal-title":"Bone"},{"key":"2021120120385060900_B91","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1210\/jc.2005-1258","article-title":"In vivo assessment of trabecular microarchitecture by high-resolution peripheral quantitative computed tomography","volume":"90","author":"Boutroy","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021120120385060900_B92","first-page":"50","article-title":"Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women","volume":"4","author":"Garnero","year":"2004","journal-title":"J. Musculoskel. Neuronal Interact."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/112\/2\/77\/437563\/cs1120077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/112\/2\/77\/437563\/cs1120077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T09:27:47Z","timestamp":1736674067000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/112\/2\/77\/68045\/New-mechanisms-and-targets-in-the-treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,11]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20060046","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,11]]}}}